Rare Diseases Act of 2002

Last updated
Rare Diseases Act of 2002
Great Seal of the United States (obverse).svg
Long titleAn Act to amend the Public Health Service Act to establish an Office of Rare Diseases at the National Institutes of Health, and for other purposes.
Acronyms (colloquial)RDA
Enacted bythe 107th United States Congress
EffectiveNovember 6, 2002
Citations
Public law 107-280
Statutes at Large 116  Stat.   1988
Codification
Titles amended 42 U.S.C.: Public Health and Social Welfare
U.S.C. sections amended
Legislative history

The Rare Disease Act of 2002 is a law passed in the United States that establishes the statutory authorization for the Office of Rare Diseases as a federal entity able to recommend a national research agenda, coordinate research, and provide educational activities for researchers. [1]

Contents

Background

A rare disease or disorder is defined in the U.S. as one affecting fewer than 200,000 Americans. There are more than 6,000 known rare diseases, and it is estimated that about 25 million Americans are affected by them (as of 2002). [2]

Prior to the RDA was the Orphan Drug Act of 1983, which was designed to facilitate the development and commercialization of drugs to treat rare diseases, termed orphan drugs . This act, however, did not provide for the creation of a centralized structure able to coordinate research or recommend agendas that would better facilitate research and education.

Legislative history

S. 1379 (Rare Diseases Act of 2001) was introduced in 2001 by Sen. Edward Kennedy (D-MA) but died in committee. [3] H.R 4013 was introduced by Rep. John Shimkus (R-IL) on May 20, 2002 and had 54 co-sponsors. [4]

It was signed into law on November 6, 2002.

Provisions

It establishes the Office of Rare Diseases under the National Institutes of Health. [5]

The law provided for a total of $24,000,000 in annual funding between 2003–2006. [6]

Impact

The NIH established the Rare Diseases Clinical Research Network in 2003 with a $51 million grant over five years in response to the law. [7]

The network consists of seven Rare Diseases Clinical Research Centers (RDCRCs) and a Data and Technology Coordinating Center (DTCC). [8]

According to Stephen Groft, Pharm.D., director of NIH's Office of Rare Diseases, "The network will facilitate increased collaboration and data sharing between investigators and patient support groups working to improve the lives of those affected by these diseases and potentially prevent or eliminate these diseases in the future." [7]

The RDCRC's will be able to utilize the resources available at the 82 General Clinical Research Centers distributed across the United States. Since the program’s launch, nearly 29,000 participants have been enrolled in RDCRC clinical studies. As of October 2014, the network is composed of around 2,600 researchers which includes NIH staff, academic investigators and members of 98 patient advocacy groups. There are 91 studies underway. [9]

For fiscal year 2014, the NIH awarded a total of $29 million to expand the Rare Diseases Clinical Research Network and study 200 rare diseases. [9]

See also

Related Research Articles

<span class="mw-page-title-main">National Institutes of Health</span> US government medical research agency

The National Institutes of Health, commonly referred to as NIH, is the primary agency of the United States government responsible for biomedical and public health research. It was founded in the late 1880s and is now part of the United States Department of Health and Human Services. Many NIH facilities are located in Bethesda, Maryland, and other nearby suburbs of the Washington metropolitan area, with other primary facilities in the Research Triangle Park in North Carolina and smaller satellite facilities located around the United States. The NIH conducts its own scientific research through the NIH Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.

A rare disease is a disease that affects a small percentage of the population. In some parts of the world, an orphan disease is a rare disease whose rarity means there is a lack of a market large enough to gain support and resources for discovering treatments for it, except by the government granting economically advantageous conditions to creating and selling such treatments. Orphan drugs are ones so created or sold.

An orphan drug is a pharmaceutical agent that is developed to treat certain rare medical conditions. An orphan drug would not be profitable to produce without government assistance, due to the small population of patients affected by the conditions. The conditions that orphan drugs are used to treat are referred to as orphan diseases. The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy that depends on the legislation of the country.

The National Institute of Mental Health (NIMH) is one of 27 institutes and centers that make up the National Institutes of Health (NIH). The NIH, in turn, is an agency of the United States Department of Health and Human Services and is the primary agency of the United States government responsible for biomedical and health-related research.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).

The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.

The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

<span class="mw-page-title-main">National Institute on Drug Abuse</span> Branch of the National Institutes of Health in the United States

The National Institute on Drug Abuse (NIDA) is a United States federal government research institute whose mission is to "advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health."

Orphanet is an organisation and knowledge base dedicated to rare diseases as well as corresponding diagnosis, orphan drugs, clinical trials and expert networks.

<span class="mw-page-title-main">Food and Drug Administration Amendments Act of 2007</span> US law

President of the United States George W. Bush signed the Food and Drug Administration Amendments Act of 2007 (FDAAA) on September 27, 2007. This law reviewed, expanded, and reaffirmed several existing pieces of legislation regulating the FDA. These changes allow the FDA to perform more comprehensive reviews of potential new drugs and devices. It was sponsored by Reps. Joe Barton and Frank Pallone and passed unanimously by the Senate.

ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and holds registrations from over 444,000 trials from 221 countries.

The National Center for Advancing Translational Sciences (NCATS) was established on December 23, 2011 and is located in Bethesda, Maryland. NCATS is one of 27 institutes and centers of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. The mission of NCATS is to transform scientific discoveries into new treatments and cures for disease that can be delivered faster to patients. The budget provided to NCATS for fiscal year 2018 is $557,373,000.

<span class="mw-page-title-main">Orphan Drug Act of 1983</span> Law passed in the United States to facilitate development of orphan drugs

The Orphan Drug Act of 1983 is a law passed in the United States to facilitate development of orphan drugs—drugs for rare diseases such as Huntington's disease, myoclonus, ALS, Tourette syndrome and muscular dystrophy which affect small numbers of individuals residing in the United States.

The Rare Diseases Clinical Research Network (RDCRN) is an initiative of the US Office of Rare Diseases Research (ORDR). RDCRN is funded by the ORDR, the National Center for Advancing Translational Sciences and collaborating institute centers. The RDCRN is designed to advance medical research on rare diseases by providing support for clinical studies and facilitating collaboration, study enrollment and data sharing. Through the RDCRN consortia, physician scientists and their multidisciplinary teams work together with patient advocacy groups to study more than 200 rare diseases at sites across the nation.

The Rare Diseases Clinical Research Network (RDCRN) Contact Registry is a patient contact registry sponsored by the National Institutes of Health (NIH). The RDCRN Contact Registry collects and stores the contact information of people who want to participate in RDCRN-sponsored research or learn more about RDCRN research. It connects patients with researchers in order to advance rare diseases research.

<span class="mw-page-title-main">National Pediatric Research Network Act of 2013</span>

National Pediatric Research Network Act of 2013 is a bill in the 113th United States Congress on February 4, 2013. It passed the United States House of Representatives and was sent to the Senate, where it was referred to the United States Senate Committee on Health, Education, Labor, and Pensions.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is part of the United States National Institutes of Health, which in turn is part of the Department of Health and Human Services. NIDDK is approximately the fifth-largest of the 27 NIH institutes. The institute's mission is to support research, training, and communication with the public in the topic areas of "diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases". As of 2021, the Director of the institute is Griffin P. Rodgers, who assumed the position on an acting basis in 2006 and on a permanent basis in 2007.

<span class="mw-page-title-main">21st Century Cures Act</span> Bill enacted by the 114th United States Congress

The 21st Century Cures Act is a United States law enacted by the 114th United States Congress in December 2016 and then signed into law on December 13, 2016. It authorized $6.3 billion in funding, mostly for the National Institutes of Health. The act was supported especially by large pharmaceutical manufacturers and was opposed especially by some consumer organizations.

<span class="mw-page-title-main">Office of Rare Diseases Research</span>

The Office of Rare Diseases Research is a division of the US National Center for Advancing Translational Sciences (NCATS) that oversees the Rare Diseases Clinical Research Network and Genetic and Rare Diseases Information Center.

References

  1. Mary Kugler. "Rare Diseases Legislation Passed". About.com. Archived from the original on July 11, 2014. Retrieved October 1, 2012.
  2. "Rare Diseases". medlineplus.gov. Retrieved 2019-11-20.
  3. "Rare Diseases Act of 2001". GovTrackUS. Retrieved October 1, 2012.
  4. "Rare Diseases Act of 2002". GovTrackUS. Retrieved October 1, 2012.
  5. Kerber, Grant (2012-10-12). "NIH Office of Rare Disease Research (ORDR)". Rare Disease Legislative Advocates. Archived from the original on 2017-04-16. Retrieved 2019-11-20.
  6. "Text of the Rare Diseases Act of 2002" (PDF). NIH. Retrieved October 1, 2012.
  7. 1 2 "NIH Establishes Rare Diseases Clinical Research Network". NIH. November 3, 2003. Archived from the original on May 2, 2012. Retrieved October 1, 2012.
  8. "Rare Diseases Clinical Research Network (RDCRN)". National Center for Advancing Translational Sciences. 2017-11-07. Retrieved 2019-11-20.
  9. 1 2 "NIH funds research consortia to study more than 200 rare diseases". National Institutes of Health. October 8, 2014. Retrieved December 18, 2015.